Newsroom

< BACK TO NEWSROOM

Select suPAR References

October 5, 2020

1) Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J. Modification of kidney barrier function by the urokinase receptor. Nature Medicine, 2008; 14:55-63 (PMID: 18084301)

2) Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J. Circulating urokinase receptor as a cause of focal segmental. Nature Medicine, 2011:17:952-60 (PMID: 21804539)

3) Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, Burke GW, Bruneval P, Naesens M, Jackson A, Alachkar N, Canaud G, Legendre C, Anglicheau D, Reiser J, Sarwal MM. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Science Translation Medicine, 2014; 6:256 (PMID: 25273097)

4) Trachtman H, Benzing T, Sever S, Harris RC, Reiser J. The grand challenge of nephrology. Frontiers in Medicine, 2014; 1:28 (PMID: 25593903)

5) Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwan S, Altintas MM, Wei C, Hotton LA, French AL, Sperling LS, LerakisS, Quyyumi AA, Reiser J. Soluble urokinase receptor and chronic kidney disease. NEJM, 2015; 373:1916-1925 (PMID 26539835)

6) Hahm E, Wei C, Fernandez I, Li J, Tardi NJ, Tracy M, Wadhwani S, Cao X, Peev V, Zloza A, Lusciks J, Hayek SS, O’Connor C, Bitzer M, Gupta V, Sever S, Sykes DS, Scadden DT, Reiser J. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney diseases. Nature Medicine, 2016; 23(1):100-106 (PMID: 27941791)

7) Schaefer F, Trachtman H, Wühl E, Kirchner M, Hayek SJ, Anarat A, Duzova A, Mir S, Paripovic D, Yilmaz A, Lugani F, Arbeiter K, Litwin M, Oh J, Matteucci MC, Gellermann J, Wygoda S, Jankauskiene A, Klaus G, Dusek J, Testa S, Zurowska A, Afonso AC, Tracy M, Wei C, Sever S, Smoyer W, Reiser J. Association of serum soluble urokinase receptor levels with progression of kidney disease in children. JEMA Pediatrics, 2017: 171(11):172914 (PMID: 28873129)

8) Drechsler C, Hayek SS, Wei C, Sever S, Genser B, Krane V, Meinitzer A, März W, Wanner C, Reiser J. Soluble urokinase plasminogen activator receptor and outcomes in patients with diabetes on hemodialysis. Clin J Am Soc Nephrol., 2017; 12(8):1265-1273 (PMID: 28495863)

9) Hayek SS, Ko YA, Awad M, Ahmed H, GrayB, Hosny MK, Aida H, Tracy MJ, Wei C, Sever S, Reiser J, Quyyumi AA. Cardiovascular disease biomarkers and suPAR in predicting decline in renal function: A prospective cohort study. Kidney International Reports, 2017; 2 (3):425-432 (PMID: 29142970)

10) Salim S. Hayek, M.D., David E. Leaf, M.D., Ayman Samman Tahhan, M.D., Mohamad Raad, M.D., Shreyak Sharma, M.B., B.S., Sushrut S. Waikar, M.D., M.P.H., Sanja Sever, Ph.D., Alex Camacho, Ph.D., Xuexiang Wang, M.D., Ph.D., Ranadheer R. Dande, M.D., Nasrien E. Ibrahim, M.D., Rebecca M. Baron, M.D., Mehmet M. Altintas, Ph.D., Changli Wei, M.D., Ph.D., David Sheikh‑Hamad, M.D., Jenny S.‑C. Pan, M.D., Michael W. Holliday, Jr., M.D., Ph.D., James L. Januzzi, M.D., Steven D. Weisbord, M.D., Arshed A. Quyyumi, M.D., and Jochen Reiser, M.D., Ph.D.  Soluble Urokinase Receptor and Acute Kidney Injury. NEJM 2020;382:416-26. (DOI: 10.1056/NEJMoa1911481)

11) Tariq U. Azam, Husam R. Shadid, Pennelope Blakely, Patrick O’Hayer, Hanna Berlin, Michael Pan, Peiyao Zhao, Lili Zhao, Subramaniam Pennathur,4 Rodica Pop-Busui, Izzet Altintas, Jens Tingleff, Marius A. Stauning , Ove Andersen, Maria-Evangelia Adami, Nicky Solomonidi, Maria Tsilika, Pinkus Tober-Lau, Eleni Arnaoutoglou, Verena Keitel, Frank Tacke, Athanasios Chalkias, Sven H. Loosen, Evangelos J. Giamarellos-Bourboulis, Jesper Eugen-Olsen, Jochen Reiser, and Salim S. Hayek.  International Study of Inflammation in COVID-19: Soluble Urokinase Receptor (SuPAR) in COVID-19–Related AKI. J Am Soc Nephrol. September 2020, ASN.2020060829; (DOI:https://doi.org/10.1681/ASN.2020060829)

Latest News
Walden Biosciences Fully Enrolls First Cohort in Phase 2 Basket Study of WAL0921 in Chronic Kidney Diseases
Walden Biosciences Announces Research Collaboration with World Renowned Genetic Epidemiologist to Advance Work on Causal Role of suPAR in Chronic Kidney Disease
Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases